FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

BIOS Equity Partners III, LP

(First)

(Middle)

(Last)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fletcher Aaron G.L.					2. Issuer Name and Ticker or Trading Symbol IN8BIO, INC. [INAB]											5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				
(Last) (First) (Middle) C/O BIOS EQUITY PARTNERS 1751 RIVER RUN SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 08/16/2022											Office below	er (give title v)	Other (s below)	pecify	
(Street) FORT WORTH TX 76107				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)											6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person				
(City) (State) (Zip)																				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	ction 2A. I Exec ay/Year) if an		A. Deemed xecution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquire Disposed Of (D) (Ins			red (A) or str. 3, 4 and			nount of rities ficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial O (Instr. 4)		
								Code	v	Amount		(A) or (D)	Price R		Following Reported Transaction(s) (Instr. 3 and 4)		(1150.4)			
Common	Stock		08/16/2022					P	v	217,	891	A \$1.9		1.9	217,891		I	See footnote ⁽¹⁾⁽²⁾⁽³⁾		
Common Stock			08/16/2022					P	V	1,349	,218	A	\$1	\$1.9 3,		574,534	I	See footnote ⁽¹⁾⁽²⁾⁽³⁾		
Common Stock		08/16/2022					P	V	206,	575	A	\$1	1.9	540,287		I	See footnote ⁽¹⁾⁽²⁾⁽³⁾ (4)(7)			
Common	Stock														5	74,432	I	See footno	ote ⁽¹⁾⁽²⁾⁽³⁾	
Common Stock													1		876,624	I	See footnote ⁽¹⁾⁽²⁾⁽³⁾ (4)(9)			
Common Stock														3	59,374	I	See footno	ote ⁽¹⁾⁽²⁾⁽³⁾		
Common Stock														997,433		I	See footnote ⁽¹⁾⁽²⁾⁽³⁾ (4)(11)			
			Table II - Deriva (e.g., p														t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution Date,	Cod	nsac de (In	nstr.	of Deri Secu Acq (A) o Disp of (E	osed) r. 3, 4	Expi	ate Exer iration D nth/Day/	ate		and 7. Title and Amount of Securities Underlying Derivative Security (II 3 and 4)		f Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	de ,	v	(A)	(D)	Date Exe) rcisable	Expii Date	ration	Title	or Num of Shar	nber					
	nd Address er Aaron	of Reporting P	erson [*]																	
	7	(First) Y PARTNEI SUITE 400																		
(Street)	ORTH	TX	76107																	
(City)		(State)	(Zip)																	
1. Name ar	nd Address	of Reporting P	erson			1														

C/O BIOS EQUIT 1751 RIVER RUN								
(Street) FORT WORTH	TX	76107						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* <u>Cavu Management, LP</u>								
(Last) C/O BIOS EQUIT 1751 RIVER RUN		(Middle)						
(Street) FORT WORTH	TX	76107						
(City)	(State)	(Zip)						
1. Name and Address BIOS Capital 1	of Reporting Person* <u>Management, LP</u>							
(Last) C/O BIOS EQUIT 1751 RIVER RUN		(Middle)						
(Street) FORT WORTH	TX	76107						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* BIOS Advisors GP, LLC								
(Last) C/O BIOS EQUIT 1751 RIVER RUN		(Middle)						
(Street) FORT WORTH	TX	76107						
(City)	(State)	(Zip)						

Explanation of Responses:

- 1. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management and Bios Equity III. Bios Advisors are entities managed and controlled by Aaron C.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.
- 2. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
- 3. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
- 4. Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities
- 5. The securities are directly held by Bios Fund III NT.
- 6. The securities are directly held by Bios Fund III QP.
- 7. The securities are directly held by Bios Fund III.
- 8. The securities are directly held by Bios Fund II, LP ("Bios Fund II").
- 9. The securities are directly held by Bios Fund II QP.
- $10. \ \mbox{The securities}$ are directly held by Bios Fund II NT.
- 11. The securities are directly held by BIOS Incysus.

Remarks

This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The second Form 4 will be filed by Leslie W. Kreis as the designated filer.

/s/ Aaron G.L. Fletcher 08/16/2022

Bios Equity Partners III, LP
By: Bios Capital
Management, LP, its general
partner By: Bios Advisors GP,
LLC, its general partner By:
/s/ Aaron Glenn Louis
Fletcher, Manager

<u>Cavu Management, LP By:</u> <u>08/16/2022</u> <u>Cavu Advisors, LLC, its</u>

general partner By: /s/ Leslie W. Kreis, Jr, Manager

Bios Capital Management, LP

By: Bios Advisors GP, LLC, its general partner By: /s/ 08/16/2022

its general partner By: /s/ Aaron Glenn Louis Fletcher,

Manager

Bios Advisors GP, LLC By:

/s/ Aaron Glenn Louis

** Signature of Reporting Person

Fletcher, Manager

n Date

08/16/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.